Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the globe. The spectrum of disease is broad but among hospitalized patients with COVID-19, respiratory failure from acute respiratory distress syndrome is the leading cause of mortality. There is an urgent need for an effective treatment. The current focus has been developing novel therapeutics, including antivirals, protease inhibitors, vaccines and targeting the overactive cytokine response with anti-cytokine therapy. The overproduction of early response proinflammatory cytokines results in what has been described as a "cytokine storm" is leading eventually to death when the cells fail to terminate the inflammatory response. Accumulating evidence shows that inflammatory cytokines induce selectin ligands that play a crucial role in the pathogenesis of inflammatory diseases by mediating leukocyte migration from the blood into the tissue. Thus, the selectins and selectin ligands represent a promising therapeutic target for the treatment of COVID-19. In this paper, potential pan-selectin inhibitors were identified employing a virtual screening using a docking procedure. For this purpose, the Asinex and ZINC databases of ligands, including approved drugs, biogenic compounds and glycomimetics, altogether 923,602 compounds, were screened against the P-, L- and E-selectin. At first, the experimentally confirmed inhibitors were docked into all three selectins' carbohydrate recognition domains to assess the suitability of the screening procedure. Finally, based on the evaluation of ligands binding, we propose 10 purchasable pan-selectin inhibitors to develop COVID-19 therapeutics.

Central European Institute of Technology Masaryk University 625 00 Brno Czech Republic

Institute of Chemistry Slovak Academy of Sciences 845 38 Bratislava Slovak Republic

National Centre for Biomolecular Research Faculty of Science Masaryk University 625 00 Brno Czech Republic

Zobrazit více v PubMed

Asinex . 2020. Screening Libraries (All Libraries): Asinex Corporation.

Aydt  EM, Bock  D, Wolff  G. 2010. Selectin antagonists and their potential impact for the treatment of inflammatory lung diseases. In: Hansel  TT, editor. New drugs and targets for asthma and copd. Basel: Karger. p. 175–184.

Baell  JB, Holloway  GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 53:2719–2740. PubMed

Baell  JB, Nissink  JWM. 2018. Seven year itch: pan-assay interference compounds (PAINS) in 2017-utility and limitations. ACS Chem Biol. 13:36–44. PubMed PMC

Barthel  SR, Gavino  JD, Descheny  L, Dimitroff  CJ. 2007. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets. 11:1473–1491. PubMed PMC

Bedard  PW, Kaila  N. 2010. Selectin inhibitors: A patent review. Expert Opin Ther Pat. 20:781–793. PubMed

Biancone  L, Araki  M, Araki  K, Vassalli  P, Stamenkovic  I. 1996. Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med. 183:581–587. PubMed PMC

Binder  FPC, Ernst  B. 2011. E- and P-selectin: Differences, similarities and implications for the design of P-selectin antagonists. Chimia. 65:210–213. PubMed

Binder  FPC, Lemme  K, Preston  RC, Ernst  B. 2012. Sialyl Lewisx: A "pre-organized water oligomer"?  Angewandte Chemie-International Edition. 51:7327–7331. PubMed

Brostjan  C, Anrather  J, Csizmadia  V, Natarajan  G, Winkler  H. 1997. Glucocorticoids inhibit E-selectin expression by targeting NF-kappa B and not ATF/c-Jun. J Immunol. 158:3836–3844. PubMed

Calosso  M, Tambutet  G, Charpentier  D, St-Pierre  G, Vaillancourt  M, Bencheqroun  M, Gratton  JP, Prevost  M, Guindon  Y. 2014. Acyclic tethers mimicking subunits of polysaccharide ligands: Selectin antagonists. ACS Med Chem Lett. 5:1054–1059. PubMed PMC

Chaput  L, Mouawad  L. 2017. Efficient conformational sampling and weak scoring in docking programs? Strategy of the wisdom of crowds. J Chem. 9:37. PubMed PMC

Cronstein  BN, Molad  Y, Reibman  J, Balakhane  E, Levin  RI, Weissmann  G. 1995. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Investig. 96:994–1002. PubMed PMC

Drickamer  K. 1993. Evolution of Ca2+-dependent animal lectins. Prog Nucleic Acid Res Mol Biol. 45(45):207–232. PubMed

Ebel  ME, Awe  O, Kaplan  MH, Kansas  GS. 2015. Diverse inflammatory cytokines induce selectin ligand expression on murine CD4 T cells via p38 alpha MAPK. J Immunol. 194:5781–5788. PubMed PMC

Egger  J, Weckerle  C, Cutting  B, Schwardt  O, Rabbani  S, Lemme  K, Ernst  B. 2013. Nanomolar E-selectin antagonists with prolonged half-lives by a fragment-based approach. J Am Chem Soc. 135:9820–9828. PubMed

Ernst  B, Magnani  JL. 2009. From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov. 8:661–677. PubMed PMC

Friesner  RA, Banks  JL, Murphy  RB, Halgren  TA, Klicic  JJ, Mainz  DT, Repasky  MP, Knoll  EH, Shelley  M, Perry  JK  et al.  2004. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 47:1739–1749. PubMed

Friesner  RA, Murphy  RB, Repasky  MP, Frye  LL, Greenwood  JR, Halgren  TA, Sanschagrin  PC, Mainz  DT. 2006. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 49:6177–6196. PubMed

Gilson  MK, Liu  TQ, Baitaluk  M, Nicola  G, Hwang  L, Chong  J. 2016. BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res. 44:D1045–D1053. PubMed PMC

Gouge-Ibert  V, Pierry  C, Poulain  F, Serre  AL, Largeau  C, Escriou  V, Scherman  D, Jubault  P, Quirion  JC, Leclerc  E. 2010. Synthesis of fluorinated C-mannopeptides as sialyl Lewis(x) mimics for E- and P-selectin inhibition. Bioorg Med Chem Lett. 20:1957–1960. PubMed

Graves  BJ, Crowther  RL, Chandran  C, Rumberger  JM, Li  S, Huang  KS, Presky  DH, Familletti  PC, Wolitzky  BA, Burns  DK. 1994. Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains. Nature. 367:532–538. PubMed

Greenwood  JR, Calkins  D, Sullivan  AP, Shelley  JC. 2010. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comput Aided Mol Des. 24:591–604. PubMed

Halgren  TA, Murphy  RB, Friesner  RA, Beard  HS, Frye  LL, Pollard  WT, Banks  JL. 2004. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 47:1750–1759. PubMed

Harder  E, Damm  W, Maple  J, Wu  CJ, Reboul  M, Xiang  JY, Wang  LL, Lupyan  D, Dahlgren  MK, Knight  JL  et al.  2016. OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput. 12:281–296. PubMed

Horby  P, Lim  WS, Emberson  JR, Mafham  M, Bell  JL, Linsell  L, Staplin  N, Brightling  C, Ustianowski  A, Elmahi  E  et al.  2020. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med.  384:693–704. doi: 10.1101/2020.06.22.20137273. PubMed DOI PMC

Irwin  JJ, Shoichet  BK. 2005. ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model. 45:177–182. PubMed PMC

Irwin  JJ, Sterling  T, Mysinger  MM, Bolstad  ES, Coleman  RG. 2012. ZINC: A free tool to discover chemistry for biology. J Chem Inf Model. 52:1757–1768. PubMed PMC

Kaila  N, Thomas  BE. 2002. Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitors. Med Res Rev. 22:566–601. PubMed

Kaila  N, Thomas  BE. 2003. Selectin inhibitors. Expert Opin Ther Pat. 13:305–317. PubMed

Kansas  GS. 1996. Selectins and their ligands: Current concepts and controversies. Blood. 88:3259–3287. PubMed

Karp  JM, Teol  GSL. 2009. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell. 4:206–216. PubMed

Kerr  KM, Auger  WR, Marsh  JJ, Comito  RM, Fedullo  RL, Smits  GJ, Kapelanski  DP, Fedullo  PF, Channick  RN, Jamieson  SW  et al.  2000. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 162:14–20. PubMed

Kim  YJ, Varki  A. 1997. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J. 14:569–576. PubMed

Kranich  R, Busemann  AS, Bock  D, Schroeter-Maas  S, Beyer  D, Heinemann  B, Meyer  M, Schierhorn  K, Zahlten  R, Wolff  G  et al.  2007. Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 50:1101–1115. PubMed

Kuhaudomlarp  S, Siebs  E, Shanina  E, Topin  J, Joachim  I, Silva Figueiredo Celestino Gomes  P, Varrot  A, Rognan  D, Rademacher  C, Imberty  A  et al.  2021. Non-carbohydrate glycomimetics as inhibitors of calcium(II)-binding lectins. Angew Chem Int Ed. doi: 10.1002/anie.202013217. PubMed DOI PMC

Lasky  LA. 1995. Selectin-carbohydrate interactions and the initiation of the inflammatory response. Annu Rev Biochem. 64:113–139. PubMed

Ludwig  RJ, Schon  MP, Boehncke  WH. 2007. P-selectin: A common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets. 11:1103–1117. PubMed

Mannori  G, Crottet  P, Cecconi  O, Hanasaki  K, Aruffo  A, Nelson  RM, Varki  A, Bevilacqua  MP. 1995. Differential colon-cancer cell-adhesion to E-selectin, P-selectin, and L-selectin - role of mucin type glycoproteins. Cancer Res. 55:4425–4431. PubMed

Mazo  IB, Gutierrez-Ramos  JC, Frenette  PS, Hynes  RO, Wagner  DD, von Andrian  UH. 1998. Hematopoietic progenitor cell rolling in bone marrow microvessels: Parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med, 188:465–474. PubMed PMC

Meduri  GU, Kohler  G, Hendley  S, Tolley  E, Stentz  F, Postlethwaite  A. 1995. Inflammatory cytokines in the bal of patients with ARDS - persistent elevation over time predicts poor outcome. Chest. 108:1303–1314. PubMed

Mehta-D'souza  P, Klopocki  AG, Oganesyan  V, Terzyan  S, Mather  T, Li  ZH, Panicker  SR, Zhu  C, McEver  RP. 2017. Glycan bound to the selectin low affinity state engages Glu-88 to stabilize the high affinity state under force. J Biol Chem. 292:2510–2518. PubMed PMC

Merad  M, Martin  JC. 2020. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat Rev Immunol. 20:355–362. PubMed PMC

Merzaban  JS, Burdick  MM, Gadhoum  SZ, Dagia  NM, Chu  JT, Fuhlbrigge  RC, Sackstein  R. 2011. Analysis of glycoprotein E-selectin ligands on human and mouse marrow cells enriched for hematopoietic stem/progenitor cells. Blood. 118:1774–1783. PubMed PMC

Montreal Heart Institute . 2020. New clinical study: Potential treatment for coronavirus will be tested in Canada as of today: BioSpace.

Poppe  L, Brown  GS, Philo  JS, Nikrad  PV, Shah  BH. 1997. Conformation of sLe(x) tetrasaccharide, free in solution and bound to E-, P-, and L-selectin. J Am Chem Soc. 119:1727–1736.

Preston  RC, Jakob  RP, Binder  FPC, Sager  CP, Ernst  B, Maier  T. 2016. E-selectin ligand complexes adopt an extended high-affinity conformation. J Mol Cell Biol. 8:62–72. PubMed PMC

Reyes  AZ, Hu  KA, Teperman  J, Wampler Muskardin  TL, Tardif  JC, Shah  B, Pillinger  MH. 2020. Anti-inflammatory therapy for COVID-19 infection: The case for colchicine. Ann Rheum Dis. 1–8. doi: 10.1136/annrheumdis-2020-219174. PubMed DOI PMC

Romano  SJ, Slee  DH. 2001. Targeting selectins for the treatment of respiratory diseases. Curr Opin Investig Drugs. 2:907–913. PubMed

Ruan  QR, Yang  K, Wang  WX, Jiang  LY, Song  JX. 2020. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China (vol 17, pg 851, 2020). Intensive Care Med. 46:1294–1297. PubMed PMC

Ruster  B, Gottig  S, Ludwig  RJ, Bistrian  R, Muller  S, Seifried  E, Gille  J, Henschler  R. 2006. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood. 108:3938–3944. PubMed

Sackstein  R, Merzaban  JS, Cain  DW, Dagia  NM, Spencer  JA, Lin  CP, Wohlgemuth  R. 2008. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med. 14:181–187. PubMed

Sahin  AO, Buitenhuis  M. 2012. Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells. Cell Adh Migr. 6:39–48. PubMed PMC

Sastry  GM, Adzhigirey  M, Day  T, Annabhimoju  R, Sherman  W. 2013. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 27:221–234. PubMed

Shelley  JC, Cholleti  A, Frye  LL, Greenwood  JR, Timlin  MR, Uchimaya  M. 2007. Epik: A software program for pK (a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des. 21:681–691. PubMed

Somers  WS, Tang  J, Shaw  GD, Camphausen  RT. 2000. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell. 103:467–479. PubMed

Sterling  T, Irwin  JJ. 2015. ZINC 15-ligand discovery for everyone. J Chem Inf Model. 55:2324–2337. PubMed PMC

Tvaroška  I, Chandrabose  S, Koča  J. 2020. Selectins—The two Dr. Jekyll and Mr. Hyde faces of adhesion molecules—A review. Molecules. 25. PubMed PMC

Valverde  P, Arda  A, Reichardt  NC, Jimenez-Barbero  J, Gimeno  A. 2019. Glycans in drug discovery. Fortschr Med. 10:1678–1691. PubMed PMC

Videira  PA, Marcelo  F, Grewal  RK. 2017. Glycosyltransferase inhibitors: A promising strategy to pave a path from laboratory to therapy. In: Carbohydrate chemistry: Chemical and biological approaches. London (UK): The Royal Society of Chemistry.

Wang  S, Vidal  S. 2013. Recent design of glycosyltransferase inhibitors. In: Rauter  AP, Lindhorst  TK, editors. Carbohydrate Chemistry: Chemical and Biological Approaches, Vol. 39. Cambridge: Royal Society of Chemistry. p. 78–101.

Woelke  AL, Kuehne  C, Meyer  T, Galstyan  G, Dernedde  J, Knapp  EW. 2013. Understanding selectin counter-receptor binding from electrostatic energy computations and experimental binding studies. J Phys Chem B. 117:16443–16454. PubMed

Woodside  DG, Vanderslice  P. 2008. Cell adhesion antagonists - therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs. 22:85–100. PubMed

Yang  J, Hirata  T, Croce  K, Merrill-Skoloff  G, Tchernychev  B, Williams  E, Flaumenhaft  R, Furie  BC, Furie  B. 1999. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J Exp Med. 190:1769–1782. PubMed PMC

Zhou  F, Yu  T, Du  RH, Fan  GH, Liu  Y, Liu  ZB, Xiang  J, Wang  YM, Song  B, Gu  XY  et al.  2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 395:1054–1062. PubMed PMC